4DMedical files FDA 510(k) submission for CT:VQ™, a non-contrast CT-based lung imaging software product for assessing both ventilation (V) and perfusion (Q) in the lungs.
CT:VQ™ represents a revolution in ventilation perfusion imaging, solving key clinical and logistical limitations across all forms of nuclear ventilation perfusion imaging.
CT:VQ™ solves key clinical and logistical limitations across all forms of nuclear VQ imaging: • No radiotracers – improved scheduling and accessibility • Simplified workflows – integrated into routine CT imaging without any additional infrastructure • Higher resolution and quantification without artifacts caused by clumping or leakage of contrast • Large install base – leverages the ~14,500 installed CT scanners across the U.S. healthcare system, including rural and smaller healthcare facilities, which may not have existing nuclear VQ infrastructure
With the clinical and logistical advantages CT:VQ™ has over traditional nuclear VQ imaging modalities, 4DMedical believes it can rapidly capture a significant part of this market, and over time expects to displace 100% of all nuclear VQ scans.
CYC Price at posting:
$1.18 Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)